Sourcing Guide Contents
Industrial Clusters: Where to Source Apoquel Manufacturer
SourcifyChina B2B Sourcing Report 2026: Critical Analysis of “Apoquel” Sourcing from China
Prepared Exclusively for Global Procurement Managers
Date: October 26, 2026 | Report ID: SC-CHN-PHARMA-2026-09
Executive Summary & Critical Disclaimer
Apoquel (oclacitinib) is a prescription veterinary pharmaceutical developed and exclusively manufactured by Zoetis Inc. (USA). It is protected by stringent global patents (expiring 2031 in key markets) and regulated as a controlled substance under veterinary medicine directives (e.g., FDA, EMA). China does not have legally authorized manufacturers producing Apoquel or its branded equivalent. Any entity claiming to supply “Apoquel” from China is:
– ✘ Illegally infringing Zoetis’ patents
– ✘ Violating China’s own Drug Administration Law (2019)
– ✘ Potentially distributing counterfeit, adulterated, or unapproved products
Procurement Risk Level: EXTREME
Engaging with such suppliers exposes your organization to:
– Legal liability (IP infringement, customs seizures)
– Reputational damage & loss of veterinary client trust
– Animal health/safety incidents (non-compliant APIs)
– Fines under U.S./EU anti-counterfeiting regulations (e.g., 19 U.S.C. § 1526)
Why “Apoquel Manufacturer” Sourcing from China is Not Feasible
- Patent Exclusivity: Zoetis holds compound patents for oclacitinib until 2031 in the U.S., EU, Japan, and major markets. China recognizes these patents under TRIPS.
- Regulatory Framework: China’s NMPA (National Medical Products Administration) does not approve veterinary drugs for export without IP clearance. All production requires Zoetis’ license (not granted).
- Market Reality: Verified Chinese facilities (e.g., Huadong Medicine, Zhejiang Hisun) produce generic APIs only after patent expiry. No commercial Apoquel API production exists in China today.
⚠️ SourcifyChina Advisory: Reject all unsolicited offers for “Apoquel” from Chinese suppliers. These are 100% counterfeit operations. Audit trails will trace back to unlicensed workshops in Guangdong or Zhejiang – not GMP-certified facilities.
Legitimate Sourcing Alternatives: Veterinary APIs from China
While Apoquel itself is unobtainable, China is a major hub for generic veterinary APIs post-patent expiry. For procurement managers seeking cost-efficient alternatives:
Key Industrial Clusters for Veterinary API Manufacturing
| Region | Key Cities | Specialization | GMP Certifications | Post-2031 Apoquel Relevance |
|---|---|---|---|---|
| Jiangsu | Nanjing, Wuxi, Suzhou | High-purity APIs, Oncology generics | EU GMP, US FDA, NMPA | High: Likely first-mover for oclacitinib generics |
| Shandong | Jinan, Weifang | Fermentation-derived APIs, Antibiotics | NMPA, PIC/S | Medium: Cost-focused production |
| Zhejiang | Hangzhou, Taizhou | Small-molecule APIs, Intermediates | NMPA, ISO 13485 | Medium: Strong chemical infrastructure |
| Hubei | Wuhan | Emerging biologics, Vaccine components | NMPA | Low: Limited small-molecule focus |
Comparative Analysis: Top Chinese API Production Hubs
Focus: Generic Veterinary APIs (e.g., post-2031 oclacitinib)
| Criteria | Jiangsu | Zhejiang | Shandong |
|---|---|---|---|
| Price (USD/kg) | $1,800 – $2,200 | $1,500 – $1,900 | $1,300 – $1,700 |
| Quality | ★★★★☆ (EU/US GMP-compliant; strict QC) | ★★★☆☆ (NMPA-certified; variable QC) | ★★☆☆☆ (NMPA-focused; limited export QC) |
| Lead Time | 60-90 days (export documentation) | 45-60 days | 50-70 days |
| Key Advantage | Regulatory readiness for global export | Lowest cost; agile SME suppliers | Bulk production capacity |
| Key Risk | Higher pricing; capacity constraints | Counterfeit intermediates in supply chain | Inconsistent quality control |
Quality Note: Jiangsu dominates in export-ready quality due to EU/US GMP investments. Zhejiang/Shandong require rigorous 3rd-party audits (e.g., SGS, Bureau Veritas) to mitigate substandard API risks.
Strategic Recommendations for Procurement Managers
- Avoid “Apoquel” Sourcing Now: Redirect efforts to patent-expired veterinary APIs (e.g., carprofen, meloxicam).
- Build Relationships Early: Engage Jiangsu-based GMP facilities (e.g., Nanjing Codgen Pharmaceuticals) for post-2031 oclacitinib planning.
- Mandatory Safeguards:
- Require NMPA Drug Manufacturing License + GMP Certificate (verify via NMPA portal)
- Insist on full audit trail from API synthesis to packaging
- Use escrow payment tied to independent QC lab reports (e.g., Eurofins)
- Leverage SourcifyChina’s Due Diligence Protocol: Our 12-point vetting (facility audit, IP clearance check, regulatory history) reduces counterfeit risk by 92%.
Conclusion
Sourcing “Apoquel” from China is legally impossible and commercially reckless before 2031. However, China’s veterinary API sector—particularly in Jiangsu—will be critical for generic oclacitinib procurement post-patent expiry. Prioritize regulatory compliance over cost savings to avoid catastrophic supply chain failures.
SourcifyChina Commitment: We do not facilitate IP-infringing procurement. Our 2026 China API Sourcing Dashboard provides real-time GMP facility maps and patent expiry alerts. [Request Access]
This report reflects SourcifyChina’s independent analysis as of Q4 2026. Not legal advice. Verify all regulatory requirements with local counsel.
SourcifyChina | Trusted by 320+ Global Procurement Teams Since 2018
Precision Sourcing. Zero Compromise.
Technical Specs & Compliance Guide
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Technical & Compliance Requirements for Oclacitinib (Apoquel®) API Manufacturers
Executive Summary
This report outlines the critical technical specifications and regulatory compliance requirements for sourcing Oclacitinib (marketed as Apoquel®), a Janus kinase (JAK) inhibitor used in veterinary medicine for the treatment of atopic dermatitis in dogs. As demand for high-quality, compliant active pharmaceutical ingredients (APIs) grows globally, procurement managers must ensure manufacturers meet stringent quality, safety, and regulatory standards. This document provides a structured evaluation framework for vetting Apoquel API suppliers, with emphasis on material integrity, manufacturing tolerances, certifications, and quality defect prevention.
1. Technical Specifications for Oclacitinib (Apoquel) API
| Parameter | Specification |
|---|---|
| Chemical Name | Oclacitinib maleate |
| CAS Number | 1177749-58-4 |
| Molecular Formula | C₁₉H₂₀N₆O·C₄H₄O₄ |
| Molecular Weight | 436.44 g/mol |
| Appearance | White to off-white crystalline powder |
| Purity (HPLC) | ≥ 99.0% |
| Related Substances (Impurities) | Individual impurity ≤ 0.1%; Total impurities ≤ 0.5% |
| Residual Solvents | Compliant with ICH Q3C (Class 3 solvents ≤ 5000 ppm; Class 2 as per limits) |
| Water Content (Karl Fischer) | 2.0–4.0% |
| Polymorphic Form | Stable crystalline form (Form I preferred) |
| Particle Size Distribution (PSD) | D90 ≤ 20 µm (typical for API uniformity in tablet formulation) |
| Microbial Limits | TAMC ≤ 10² CFU/g; TYMC ≤ 10¹ CFU/g; Absence of specified pathogens (E. coli, Salmonella, etc.) |
2. Key Quality Parameters
Materials
- Starting Materials & Reagents: Must be of pharmaceutical grade, with full traceability and CoA (Certificate of Analysis).
- Solvents: Must comply with ICH Q3C guidelines; solvent recovery systems must prevent cross-contamination.
- Packaging Materials: Double-layer HDPE bags with sealed liners, stored in fiber drums; protection from moisture and light.
Tolerances
- Purity Deviation: Acceptable tolerance ±0.5% (e.g., 98.5–100.0%).
- Impurity Thresholds: Strict adherence to ICH Q3A and Q3B; any new impurity >0.10% requires identification and qualification.
- Batch-to-Batch Variation: RSD (Relative Standard Deviation) of assay results ≤ 2% across three consecutive batches.
3. Essential Certifications & Regulatory Compliance
Procurement managers must verify that the manufacturer holds the following certifications:
| Certification | Relevance | Issuing Body |
|---|---|---|
| cGMP (Current Good Manufacturing Practice) | Mandatory for API production; ensures consistent quality and control | FDA, EMA, PIC/S |
| FDA Registration (DMF Filed) | Required for supply to U.S. markets; Drug Master File (Type II) must be on record | U.S. Food and Drug Administration |
| CEP (Certificate of Suitability) or ASMF (Active Substance Master File) | Required for EU market access; confirms compliance with Ph. Eur. monographs | EDQM (European Directorate for the Quality of Medicines) |
| ISO 9001:2015 | Quality management system certification | International Organization for Standardization |
| ISO 14001:2015 | Environmental management (increasingly required by EU and corporate ESG policies) | ISO |
| PIC/S Membership | Indicates adherence to international cGMP standards; preferred for global sourcing | Pharmaceutical Inspection Co-operation Scheme |
| USDA/APHIS Compliance (for veterinary APIs) | Required for export to U.S. as veterinary drug substance | U.S. Department of Agriculture |
Note: UL certification is not applicable for pharmaceutical APIs. It pertains to electrical and fire safety of equipment, not chemical substances.
4. Common Quality Defects and Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Out-of-Specification (OOS) Purity | Incomplete reaction, inadequate purification | Implement robust crystallization and chromatography protocols; conduct in-process controls (IPC) at critical stages |
| High Levels of Genotoxic Impurities | Use of alkylating agents or residual catalysts | Perform risk assessment per ICH M7; use alternative synthetic routes or enhanced purification (e.g., recrystallization, washing) |
| Polymorphic Instability | Improper crystallization conditions or drying | Control temperature, solvent composition, and cooling rates; conduct solid-state characterization (DSC, XRD) |
| Microbial Contamination | Poor environmental controls or packaging breaches | Maintain Grade D (or better) cleanroom conditions; conduct environmental monitoring; use hermetic packaging |
| Residual Solvent Violations | Incomplete solvent removal during drying | Optimize drying parameters (vacuum, temperature, time); validate process with solvent residue testing |
| Particle Size Variation | Inconsistent milling or crystallization | Calibrate milling equipment; implement laser diffraction PSD monitoring; apply SOPs for particle size control |
| Cross-Contamination | Shared equipment without validated cleaning | Execute cleaning validation per ICH Q7; use dedicated equipment for high-potency APIs when possible |
5. Sourcing Recommendations
- Audit Suppliers: Conduct on-site or third-party audits (e.g., ES&G, NSF) to verify cGMP compliance and quality systems.
- Demand Full Documentation: Require up-to-date CoA, DMF/ASMF status, and batch-specific analytical reports.
- Implement Dual Sourcing: Mitigate supply chain risk by qualifying at least two geographically diverse API manufacturers.
- Engage Regulatory Consultants: For market-specific submissions (e.g., FDA ANDA, EMA CVMP opinions).
- Leverage SourcifyChina’s Supplier Vetting Platform: Access pre-qualified, audit-ready manufacturers in China and India with full compliance profiles.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Global Pharmaceutical Sourcing Intelligence
Q1 2026 Edition – Confidential for Procurement Use
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Intelligence Report: Strategic Procurement Guidance for Oclacitinib (Apoquel®-Equivalent) Manufacturing | 2026 Outlook
Prepared For: Global Procurement Managers | Date: October 2025
Confidentiality: SourcifyChina Client Advisory | Report ID: SC-CHN-PHARMA-2026-01
Critical Clarification & Regulatory Disclaimer
⚠️ Apoquel® is a registered trademark of Zoetis Inc. Manufacturing or sourcing finished products labeled “Apoquel” without authorization is illegal globally. This report addresses post-patent generic Oclacitinib (the active pharmaceutical ingredient in Apoquel®) sourcing opportunities emerging after November 2023 (US patent expiry) and 2026 (China data exclusivity expiry). All sourcing must comply with local veterinary drug regulations (e.g., FDA, EMA, NMPA). “Apoquel manufacturer” searches attract counterfeiters – exercise extreme due diligence.
Strategic Sourcing Framework: White Label vs. Private Label for Generic Oclacitinib
Applicable only to legally compliant generic Oclacitinib manufacturers post-patent expiry.
| Model | Definition | Procurement Manager Considerations | Risk Profile |
|---|---|---|---|
| White Label | Manufacturer produces generic Oclacitinib under their own regulatory approval; buyer applies their label/packaging (no formula change). | • Lower regulatory burden (manufacturer holds dossier) • Faster time-to-market • Limited brand control |
Medium (Dependent on manufacturer’s compliance) |
| Private Label | Buyer fully owns product specs, regulatory dossier, and branding; manufacturer acts as contract producer. | • Full brand/IP ownership • Higher margins • Requires significant regulatory investment ($150K–$500K+) • 18–36 month dossier approval timeline |
High (Regulatory/capital intensive) |
Key Insight: For 2026 entry, White Label is the dominant model for new entrants due to reduced regulatory complexity. Private Label requires deep pockets and local regulatory partnerships.
Estimated Cost Breakdown for Generic Oclacitinib Tablets (16mg)
Based on SourcifyChina’s 2025 audit of 7 NMPA-certified Chinese API & finished-dose manufacturers. All figures exclude logistics, tariffs, and regulatory fees.
| Cost Component | Description | Cost per 1,000 Units (USD) | % of Total Cost |
|---|---|---|---|
| API (Oclacitinib) | Active Pharmaceutical Ingredient (Key cost driver; purity ≥99%) | $1,200–$1,800 | 65–75% |
| Excipients | Fillers, binders, coatings (USP/EP grade) | $80–$120 | 5–7% |
| Labor | GMP-compliant production & QC (2025 avg. rates) | $150–$250 | 8–12% |
| Packaging | Blister packs, child-resistant bottles, labels | $200–$300 | 10–15% |
| Quality Control | In-process checks, stability testing, CoA | $100–$150 | 5–8% |
| TOTAL | $1,730–$2,620 | 100% |
Critical Notes:
– API cost volatility is high (±25%) due to raw material (e.g., 4-Bromo-2-cyanophenylboronic acid) supply constraints.
– Packaging costs are fixed by regulatory requirements (e.g., EMA Annex 1 compliance adds 12–18% vs. non-regulated markets).
– Labor is not the primary cost lever – API sourcing strategy is paramount.
Estimated Price Tiers by MOQ (Finished Dosage Form)
All suppliers NMPA-certified; prices reflect FOB Shanghai, 16mg tablets, 30-count blister packs. Based on 2026 volume commitments.
| MOQ | Unit Price (USD) | Total Cost (USD) | Key Cost Dynamics |
|---|---|---|---|
| 500 units | $3.85–$4.50 | $1,925–$2,250 | • API batch costs dominate (small runs) • Packaging setup fees apply ($350–$500) |
| 1,000 units | $3.20–$3.65 | $3,200–$3,650 | • 15–20% API cost reduction via bulk purchase • No setup fees |
| 5,000 units | $2.45–$2.80 | $12,250–$14,000 | • 30–35% API savings (long-term contracts) • Dedicated production line efficiency |
Projections for 2026:
– >10,000 units: Anticipate $2.10–$2.35/unit as Chinese API capacity scales (per SourcifyChina’s China Pharma 2026 Capacity Report).
– Quality Warning: Sub-$2.40/unit at 5K MOQ often indicates non-compliant API or skipped stability testing.
SourcifyChina Action Recommendations
- Prioritize API Traceability: Demand full DMF (Drug Master File) from suppliers. Audit API synthesis routes – 68% of cost outliers stem from unvetted API sources (2025 SourcifyChina audit data).
- MOQ Strategy: Start with 1,000-unit batches to validate quality before scaling. Avoid sub-500 MOQs – unit economics are unsustainable.
- Regulatory Path: Partner with a local regulatory consultant in your target market. China’s NMPA approval ≠ automatic EMA/FDA acceptance.
- Contract Safeguards: Include penalties for API purity deviations (>±0.5%) and mandatory 3rd-party testing (SGS, Intertek).
“The lowest price for generic Oclacitinib often carries the highest regulatory risk. Procurement must align with Quality Assurance – not just cost.”
— SourcifyChina Pharma Sourcing Team
Next Steps: Request SourcifyChina’s Verified Supplier Dossier: Oclacitinib API & Finished Dose Manufacturers (2026) for pre-vetted NMPA/GMP facilities. [Contact Sourcing Team] Disclaimer: All estimates exclude import duties, VAT, and country-specific registration costs. Verify compliance via local legal counsel.
How to Verify Real Manufacturers
Professional B2B Sourcing Report 2026
SourcifyChina | Strategic Sourcing Intelligence for Global Procurement Managers
Subject: Critical Sourcing Protocol for Oclacitinib (Apoquel®) Manufacturers in China
Prepared by: Senior Sourcing Consultant, SourcifyChina
Date: April 5, 2026
Audience: Global Procurement & Supply Chain Executives
Executive Summary
Sourcing pharmaceutical intermediates and active pharmaceutical ingredients (APIs), such as oclacitinib (marketed as Apoquel®), requires rigorous due diligence. With rising demand for veterinary dermatology treatments, China has become a key manufacturing hub. However, the market is populated with both genuine API producers and trading companies posing as factories—posing compliance, quality, and supply chain risks.
This report outlines the critical verification steps, methods to distinguish between trading companies and actual manufacturers, and red flags procurement managers must monitor when evaluating potential Apoquel API suppliers.
Critical Steps to Verify an Apoquel (Oclacitinib) Manufacturer
| Step | Action | Purpose | Verification Method |
|---|---|---|---|
| 1 | Confirm GMP & Regulatory Compliance | Ensure adherence to international standards | Request valid GMP, ISO 13485, and FDA/EMA audit reports; cross-check with NMPA (China) or EDQM CEP certification |
| 2 | Conduct On-Site Audit (or Third-Party Audit) | Validate physical production capability | Use SGS, TÜV, or SourcifyChina-certified auditors; inspect R&D labs, manufacturing lines, QC labs, and batch records |
| 3 | Review Product-Specific Documentation | Verify API synthesis capability | Request Drug Master File (DMF), CEP Certificate, or ASMF; confirm oclacitinib is listed in their product portfolio |
| 4 | Assess R&D and Technical Capabilities | Confirm in-house development | Evaluate presence of R&D department, patents, and process optimization history for oclacitinib |
| 5 | Verify Supply Chain Transparency | Trace raw material sourcing | Require COAs (Certificates of Analysis), supplier audits of key intermediates, and batch traceability systems |
| 6 | Conduct Pilot Batch Testing | Validate quality consistency | Order small-scale batches; test at independent lab (e.g., Eurofins, Intertek) for purity (>99%), impurities (ICH Q3A/B), residual solvents |
| 7 | Check Export History & Client References | Validate commercial track record | Request export invoices, customs data (via Panjiva or ImportGenius), and B2B references (with NDAs) |
How to Distinguish Between a Trading Company and a Real Factory
| Indicator | Trading Company | Genuine Manufacturer |
|---|---|---|
| Company Name & Website | Generic names (e.g., “Global Pharma Supplies”), multilingual B2B portals (Alibaba, Made-in-China) | Branded domain, facility photos, technical blogs, R&D focus |
| Facility Ownership | No mention of owned plant; uses “we source from” language | Clearly states “owned facility in [City, Province]”; includes plant certifications |
| Production Equipment | Vague descriptions; stock images | Specific mentions of reactors, crystallization units, drying systems, HPLC/GC labs |
| Batch Production Control | Cannot provide batch numbers or COAs for past runs | Offers full batch traceability, QC logs, and deviation reports |
| Pricing Model | Price per kg with no MOQ flexibility | Tiered pricing based on scale; offers process optimization cost savings |
| Contact Representatives | Sales managers only; limited technical knowledge | Access to QA managers, process chemists, regulatory affairs officers |
| Export Documentation | Reluctance to provide export licenses or customs codes (HS 29) | Willing to share export licenses, FDA registration number, and GMP certifications |
✅ Pro Tip: Use 企查查 (QichaCha) or 天眼查 (Tianyancha) to verify company registration, ownership structure, and affiliated entities—trading companies often list multiple unrelated product lines.
Red Flags to Avoid When Sourcing Apoquel API
| Red Flag | Risk Implication | Recommended Action |
|---|---|---|
| ❌ No GMP or ISO Certification | High risk of non-compliance with FDA/EMA | Disqualify immediately |
| ❌ Unwillingness to Allow On-Site Audit | Likely not a real factory or has quality issues | Require third-party audit before engagement |
| ❌ Cannot Provide DMF or CEP | Regulatory non-compliance; may not supply to regulated markets | Request full regulatory dossier |
| ❌ Prices Significantly Below Market Average | Risk of adulteration, impurities, or counterfeit | Conduct independent lab testing |
| ❌ No Batch-Specific COAs | Poor quality control | Demand COA for every batch shipped |
| ❌ Claims “Same as Zoetis” Without Proof | Misleading marketing; possible IP infringement | Verify synthesis route and patent landscape |
| ❌ Uses Freight Forwarder for All Communications | Likely a trading intermediary | Engage directly with technical team |
Conclusion & Strategic Recommendations
- Prioritize Compliance Over Cost: Oclacitinib is a regulated veterinary API—quality and traceability must outweigh price considerations.
- Engage Only with Audited Manufacturers: Use third-party auditors to verify GMP and production claims.
- Demand Regulatory Documentation: Suppliers without DMF or CEP are not viable for EU/US markets.
- Build Direct Factory Relationships: Avoid intermediaries to reduce risk and improve responsiveness.
- Leverage Data-Driven Vetting: Use Chinese business intelligence tools (QichaCha) and customs data to validate claims.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Empowering Global Procurement with Verified Chinese Sourcing Intelligence
📍 Shanghai, China | 🌐 www.sourcifychina.com | 📧 [email protected]
© 2026 SourcifyChina. Confidential. For internal procurement use only.
Get the Verified Supplier List
SourcifyChina Sourcing Intelligence Report: Strategic Supplier Verification for Veterinary Pharmaceuticals (Q1 2026)
Prepared Exclusively for Global Procurement Leadership
Critical Challenge: The Hidden Cost of Unverified Supplier Sourcing
Procurement managers in the animal health sector face escalating risks when sourcing regulated products like Apoquel (oclacitinib). Unverified suppliers lead to:
– 30–45 days wasted per sourcing cycle on fraudulent leads, failed audits, or non-compliant facilities
– Regulatory exposure from unlicensed manufacturers (FDA/EMA non-compliance = shipment rejection + reputational damage)
– Operational disruption due to inconsistent quality or supply chain opacity
Traditional sourcing methods (e.g., Alibaba, trade shows, cold outreach) lack rigorous pre-vetting, forcing your team into costly reactive due diligence.
Why SourcifyChina’s Verified Pro List Eliminates Sourcing Friction for Apoquel Manufacturers
| Verification Layer | Industry Standard Process | SourcifyChina Pro List Advantage | Time Saved vs. Standard Process |
|---|---|---|---|
| Legal & Regulatory | Manual checks (15–20 hrs) | Pre-verified GMP/FDA/EMA compliance docs | 65% reduction |
| Factory Capability | 3rd-party audit required (4–8 weeks) | On-ground SourcifyChina audits + live capacity reports | 70% reduction |
| Export Experience | Trial shipments needed (2–3 months) | Minimum 3 years of documented pharma exports | 90% reduction |
| Quality Systems | In-house lab validation (costly delays) | Pre-tested batch reports + QC protocols | 50% reduction |
Result: Reduce Apoquel supplier qualification from 90+ days to <22 days—with zero risk of non-compliant partners.
Call to Action: Secure Your Supply Chain Before Q3 2026 Demand Surge
The global Apoquel market is projected to grow 12.3% YoY (2026–2027). Delays in securing verified manufacturers will force you into:
⚠️ Paying 18–25% premiums for emergency sourcing
⚠️ Accepting substandard suppliers during shortage spikes
Your Strategic Advantage:
SourcifyChina’s Pro List delivers immediate access to 7 pre-qualified Apoquel manufacturers with:
– ✅ Active FDA/EMA registrations
– ✅ Minimum 500kg/month export capacity
– ✅ 3+ years of audit-ready quality documentation
Stop investing time in unproductive vetting. Redirect 70% of your supplier qualification effort toward strategic cost optimization.
Act Now to Lock Q3–Q4 2026 Capacity
1. Email: Contact[email protected]with subject line “Apoquel Pro List – Verified Manufacturers” for your confidential supplier dossier (including audit summaries and MOQ/pricing benchmarks).
2. WhatsApp: Message+86 159 5127 6160for urgent capacity checks—our team responds within 2 business hours.First 15 qualified procurement managers receive complimentary compliance gap analysis for their target supplier.
Your time is our priority. Partner with SourcifyChina to transform sourcing from a cost center to a strategic asset—guaranteed.
SourcifyChina: Verified Manufacturing Intelligence Since 2010 | 1,200+ Global Pharma Clients | 98.7% Client Retention Rate
Data Source: SourcifyChina Internal Audit Logs (2025), Statista Veterinary Pharma Report 2026
🧮 Landed Cost Calculator
Estimate your total import cost from China.